Index

Note: page numbers in italics refer to figures.

Academic Research Organizations (ARO) 69, 70, 143
accountability
study devices 204, 278, 279
study drugs 239, 272, 276, 277
active control 184
activities, study 213–42, 244
adaptive trial design 194
adherence see compliance
adverse drug reactions (ADRs) see adverse event(s)
adverse event(s) (AE)
clinical trials 125–7
coding 294, 295
data collection 129
defined 125–6
external 126
internal 126
investigator responsibilities 129–35
IRB responsibilities 115, 135–6
postmarketing surveillance 39–43
regulations 124
relationship to study participation 130–1
serious see serious adverse event(s)
seriousness 131
severity/intensity 131
severity versus seriousness 131
terminology 124
unanticipated 128–9
vaccine-related 42
see also unanticipated problems
adverse event reporting
clinical trials 124–5
evaluating requirements 204
expedited 131–3, 137
forms 132, 259–61
investigator responsibilities 130–5
IRB responsibilities 135–6
to IRBs 110, 116
mandatory 43, 45
medical devices 279
postmarketing 41–3
rationale 124–5
regulations 124
sponsor responsibilities 136–9
voluntary 42–3, 44
advertisements 220–1
documentation of IRB approval 258
IRB approval 108, 253
Alert Report 137
animal studies 15
assent 89–90
Association for the Accreditation of Human Research Protection Programs (AAHRPP) 10, 119–20
Association of Clinical Research Professionals (ACRP) 170
Assurance of Compliance 53–4
audits 142, 154–6
common findings 161
process 156
rationale 156
regulations and guidelines 155
audit trails 156, 285, 287, 307
authorization for use of protected health information 55–6, 90–2, 97, 283
revocation 284
waivers 56, 283–4
autonomy, individuals with diminished 75
background, study 180
Beecher, Henry 6–7
Belmont Report (1979) 7, 50, 332–40
beneficence in study design 184
human subject regulations based on 52–3
informed consent 75–6, 336–8
study population 190–1
vulnerable subjects 85–7
beneficence 7, 184, 335
benefits versus risks evaluation
adverse event reporting and 125
ethics codes 329, 338–9, 341
IRB 108
Best Pharmaceuticals for Children Act 2002 10
bias 165, 195
biological products (biologics) combination products 38–9
defined 21–2
development process 14–26, 46
early or expanded access to unapproved 24–5
investigational see drugs and biologics, study
postmarketing surveillance 39–43
regulations 373
Biologics License Applications (BLA) 21
approvals in 2008 24
FDA review procedures 21–4
biologics trials case histories 264
IRB responsibilities 117
phase 4 postmarketing 40
record retention 266, 267
site audits and inspections 155
see also drugs and biologics, study
Bioresearch Monitoring Program, FDA 157

395
Clinical holds, Investigational New Drugs 17
Clinical Laboratory Improvement Act 1988 (CLIA) 253
Clinical practice 102
Clinical research 102
Clinical Research Associates (CRA) 143
documenting monitoring visits 151
electronic data review 296, 297
follow-up letters 151, 152
on-site monitoring visits 144–51
site study file review 241
source document verification 308–9
Clinical Research Coordinators (CRC) 143, 169–72
activities delegated to 169, 171
data handling 287, 295, 296, 304, 309
desirable characteristics 172
document management 246
ensuring subject retention 233–5, 237
estimating costs 208, 209, 210
evaluating time/task requirements 203–4
interactions with potential subjects 226
Investigator Meetings 219
on-site monitoring 145–6, 147, 148–9, 151
recruitment 215–16
relationship with PI 166–7
sponsor quality assurance audits 156
start-up phase activities 215–16
training and education 170
workspace 173–4
clinical trials
activities 213–42, 244
adverse events 124
competing, at same site 224–5
completion and close-out phase 240–2
data 281–311
design 183–90
documents 245–69
feasibility assessment 199–212
federally funded 51–2, 53
international 314–23
maintenance phase 230–40
organizational structure 180–1, 214
phases 17–20
process 368–9
protocols see protocol(s)
publication/reporting of results 10, 330
registration 10, 58, 329
site see site, study
start-up phase 215–30
test products see test products/articles
see also device trials; drug trials
Clinical Trials Networks (CTN) Best Practices 170
close-out phase 240–2
checklist 243, 352
documents 241, 263–6
monitoring visits 149–51
see also completion, study
Code of Federal Regulations (CFR), U.S. 7, 51–4
adverse event reporting 124
applicability to specific trials 58
assurance of compliance 53–4
audits and inspections 155
biologics 21, 373
data handling 285–6, 298, 370
essential documents 246
financial disclosure 56–8, 371
human subject protection 51–4, 370, 374–5
ICH guidelines compared 60
IND application 16, 372–3
informed consent 60, 77–90, 97, 360
Investigational Device Exemptions 30, 34–5, 373–4
IRBs 67–8, 102, 103, 371
PI responsibilities 62–6
record retention 308
responsibilities identified in 62–70
sources of information and guidance 70–1
sponsor-investigators 70
sponsor responsibilities 69–70
Title 21 51, 56–8, 370–4
Title 21 and Title 45 compared 52–3
Title 45 51–3, 55–6, 58, 374–5
coding, data 294–5
coercion 78
cohort studies 188–9
Collaborative Institutional Training Initiative (CITI) 170
College of American Pathologists (CAP) 253
combination products 38–9
Common Rule 52
Common Terminology Criteria for Adverse Events (CTCAE) dictionary 295
communication
IRBs with investigators 116–17, 258
IRBs with sponsors 117–18
modern technology 379
skills, requirements 166, 172
study close-out phase 242
with study team 217–19, 239–40
written 263
community attitudes, awareness of 105
compassionate use
investigational drugs 25
unapproved medical devices 36–7
completion, study 240–2
documents 241, 263–6
IRB notification 117
monitoring visits 149–51
see also close-out phase
compliance (adherence)
investigator with protocol 165
investigator with regulations 53–4
sponsor audits 156
subject 233–8
see also informed consent
computerized data checks 153
computers, study requirements 173, 174, 206
concurrent studies see prospective studies
confidentiality 310
adverse event reporting 43, 130
agreement 247
guidelines 285, 310
IRB responsibilities 109
see also Privacy Rule; protected health information
Confidential Master Subject Log 259, 260, 353
conflicts of interest (COI) 167–9
disclosure 168
financial 57, 58, 167, 168
investigator delegation of study activities 169
IRB members 68, 105–6, 168–9
management 168–9
non-financial sources 168
consent forms 82–5, 230, 355–61
completing 96–7
copies 60, 83, 97, 259
HIPAA compliance 90–2
IRB approval 108, 250, 251, 252–3
non-English-speaking subjects 94
reading level 93, 94
revisions 97–9, 257
sample 355–9
short 82, 83, 84, 342
signed 259
writing 92–4
written 82–3
written summary 83–5, 86, 343
see also informed consent
contact information, subject 230, 237–8, 351
continued access use, unapproved medical devices 37
Contract Research Organizations (CRO) 69, 70, 143
Contractual Agreement (financial contract) 206–7, 211, 255
costs 207–11
control, active 184
control groups 184–5
controlled substances, handling 274
Coordinators, Study see Clinical Research Coordinators
correspondence, written 263
COSTART 294
costs estimating study 207–11
indirect 208
CRA see Clinical Research Associates
CRC see Clinical Research Coordinators
CRFs see case report forms
cross-over trials 185
cross-sectional studies 190
cultural sensitivities, international trials 316–17
curriculum vitae (CV)
investigators 113, 215, 248
new PIs and subinvestigators 257
study personnel 255
DASI (Duke Activity Status Index) 182
data 281–311
blank 305
coding 294–5
computerized checks 153
conditional fields 292–3
confidentiality see confidentiality
consistency 293–4
conventions 305
corrections 302–7
data capture 304
electronic 285–6
electronic capture see electronic data capture
endpoint adjudication 310–11
guidelines and regulations 284–6
inconsistent 305
international trials 314
monitoring plans 143
outside a prespecified range 305
remote entry 307
retention 197
source 144, 288
storage/archiving 308
study site responsibilities 287–308
submission 307–8
see also documents, study; health information
Data and Safety Monitoring Board or Committee (DSMB or DSMC) 116, 196–7
databases, exemption from IRB approval 113–14
data forms 261
completion 231, 290–302
computerized checks 153
conditional data fields 292–3
design 290, 292
data forms 261
edits and queries 303–7
free text 290–1
outstanding, close-out phase 264
paper versus electronic 296

DASIA (Duke Activity Status Index)
data forms (continued)
reminder worksheets 231, 288–9
retention at end of study 264
source 229, 231, 290, 291
subject-completed 302, 303
submission 307–8
types 298–302
see also case report forms
data queries 304–7
resolving 241, 305–7
data query forms 261, 264, 306
data records, subject
complete sets 264
retention 266–7
dear health care provider letters 228
Declaration of Helsinki 6, 50, 327–31
principles of informed consent 76, 329–30
research ethics committees 102, 328
statement on placebo use 184, 331
de-identification, health information 282, 284, 310
Department of Health and Human Services (DHHS) 7, 9, 10
assurance of compliance 53–4
Code of Federal Regulations 51–2
Privacy Rule 282
site inspections 155
design, study 183–90
adaptive 194
evaluating feasibility 200–1
IRB review 108
developing countries, clinical trials in see international clinical trials
devices
Class I 29, 30
Class II 29, 30
Class III 29–30
classification 29–33
classification panels 30, 31
combination products 38–9
compassionate use of unapproved 36–7
continued access/extended investigation 37
defined 28
developing new 26–39, 47
early or expanded access to unapproved 36–7
emergency use of unapproved 36
exempt 30
FDA review 38
general controls 29
humanitarian use 36
investigational see devices, study
IRB responsibilities 32, 34, 117–18
legislation 7–8, 27–8
marketing requirements 33–5
nonsignificant risk (NSR) 30, 31–2
phase 4 postmarketing studies 40–1
postmarketing surveillance 39–43
Premarket Approval 29, 30, 34, 35
Premarket Notification 29, 33–4
regulatory classes 29–30
risk assessment 30–3
safety and effectiveness 28
significant risk (SR) 30, 31, 32, 34, 68
special controls 29
substantially equivalent 33
treatment use of unapproved 37
unanticipated adverse effects 124, 130, 135, 138–9
devices, study 278–9
accountability 204, 278, 279
disposition 264–6
labeling 278–9
management plan 272
storage 217
tracking 279
device trials 35
budget considerations 207
case histories 264
data management 285
expedited reporting of adverse effects 138–9
IRB responsibilities 67–8, 118
record retention 308
record retention period 266, 267
see also Investigational Device Exemption (IDE) studies
DHSS see Department of Health and Human Services
discontinuation, subject 235–7
dispensing, study drug 204, 274–7
documents, study 245–69
close/out/completion phase 241, 263–6
enrollment packet 224
essential 246
FDA inspection 157
long-term storage 242
maintenance phase 240, 256–63
retention see record retention
source see source documents
start-up phase 215–16, 246–55
storage space 174, 206
submission to IRBs 113, 215–16, 250
see also data; site study file
Doll, Sir Richard 190
Domain Specific Review Boards (DSRBs) 102
dose-ranging studies 19, 184
double-blind study 187
double-dummy technique 187
drop outs, study 193
drug(s)
accountability 239, 272, 276, 277
combination products 38–9, 291
eyear or expanded access to unapproved 24–5
generic or trade names 291
investigational see drugs and biologics, study
phase 4 postmarketing studies 40–1
postmarketing surveillance 39–43
drug development, new 14–26, 46
eyear or expanded access to unapproved 24–5
FDA review groups 21–4
historical background 14
IND application 16–17
marketing applications 20–1
orphan drugs 25–6
phase of clinical trials 17–20
pre-clinical studies 15
timeline 15
Drug Information Association (DIA) 170
drugs and biologics, study 272–8
accountability 239, 272, 276, 277
administration 277
dispensing/preparation 204, 274–7
disposition 197, 241, 264–6, 278
management plan 272
packaging 273
receipt 274, 275
storage 206, 274
unblinding 277–8
drug trials
adverse event reporting 130, 137
case histories 264
data management 285
inspections 155
IRB responsibilities 117
protocols 178–9
record retention 266, 267
see also Investigational New Drug (IND) studies
DSMB see Data and Safety Monitoring Board
Duke Activity Status Index (DASI) 182
Duke Clinical Research Institute (DCRI) 321–2
duration, study, budget
preparation and 209, 210
economic endpoints 182
EDC see electronic data capture
education, study site personnel
228–30
educational materials, subject 226–8, 258
efficacy, clinical trials 19–20
electronic case report forms (eCRFs) 152
completion 293, 296, 297
computerized checks 153
data queries 304–5
electronic data 285–6
back-up 307
storage/archiving 308
submission 307
electronic data capture (EDC) 296–8
advantages 296
challenges 296–7
CRC activities 203–4
equipment needed 174, 297
regulations 298
electronic patient-reported outcomes (ePRO) 302
electronic records (e-records) 285–6, 296, 370
electronic signatures 286, 298, 370
authorization form 298, 299
eligibility criteria 191
evaluating feasibility 201
IRB review 108
screening against 221–3
emancipated minors 89
emergencies, study treatment
unblinding 238
emergency research
awareness of community attitudes 105
informed consent 79–80, 111–12
IRB and sponsor communication 118
emergency use
investigational drugs 25
unapproved medical devices 36
endpoints 181–3
adjudication 310–11
composite 181
economic 182
quality of life 181–2
single 181
source document verification 153–4
surrogate 182–3
trials driven by 201
English language see language
enrollment, subject 219–28
competing trials at same site 224–5
completion 240–1
obtaining informed consent 95–6, 225–6
plan 224
screening prior to 221–3
starting 230
see also recruitment, subject
enrollment forms 298–9, 300
enrollment packet 224
equipment
estimating costs 211
study requirements 174, 205–6
equipoise, clinical 165, 184
essential documents 246
ethical issues, international trials 316–17
Ethical Principles and Guidelines for the Protection of Human
Subjects of Research see Belmont Report
ethics committees (EC) 67, 102, 328
see also Institutional Review Board
event-driven trials 194
exclusion criteria 191
Experimental Subject’s Bill of Rights (California) 61, 94, 107
exploratory Investigational New Drug studies 17–18
extended investigation, unapproved medical devices 37
fabrication 159
FACT-G 182
falsification 159
fast-track review program 23–4, 25, 26
FDA see Food and Drug Administration
feasibility, study 199–212
Federal Policy for the Protection of Human Subjects 52
Federal Register 8, 70–1
Federalwide Assurance (FWA) 53–4
fees, negotiation 208
fetuses
consent for research on 87–8
regulations protecting 53, 375
file, site study see site study file
final reports 117, 241, 264, 265
Final Rule 71
financial conflicts of interest 57, 58, 167, 168
financial contract see Contractual Agreement
financial disclosure
collection of information 250
final report 267
regulations 56–8, 168, 371
studies covered by regulations 56
follow-up
forms 300, 301, 308
lost to 193, 237–8
visits, subject 231–3, 235
Food, Drug and Cosmetic Act 1938
3, 14, 320
Kefauver-Harris Amendment 5, 14
Medical Device Amendments 7, 27
Food and Drug Administration (FDA)
Advisory Committees 22, 38
Bioresearch Monitoring Program 157
Code of Federal Regulations Title 21 51
combination products 39
drug development process 14
eyearly or expanded access to investigational drugs 25
fast-track program 23–4, 25, 26
financial disclosure reporting 57
guidance documents 59, 71, 128–9
history 3, 4–5, 7–9, 14
IND application 16–17
IND safety reports 137
Information Sheet Guidances 71
inspections 154, 155, 157–62
IRB registration 120
medical devices 27–38
New Drug Application 21
Notice of Proposed Rulemaking (1992) 286
postmarketing surveillance 40–3
review groups 21–4
risk-benefit evaluation 125
study protocol review and approval 178
unanticipated problems 128–9
Web site 71
Food and Drug Administration Act 1988 7
Food and Drug Administration Amendments Act 2007 10, 58
Food and Drug Administration Modernization Act 1997 8–9, 23, 28
Food and Drugs Act 1906 2–3, 14, 50
Form FDA 482 157, 158
Form FDA 483 159, 160
Form FDA 1571 16, 17
Form FDA 1572 62–5, 155, 169, 248–50, 361–2
updating 257, 267
Form FDA 2892 29
Form FDA 3454 57
Form FDA 3455 57
Form FDA 3500 42–3, 44, 279
Form FDA 3500A 43, 45, 279
Framingham Heart Study 189
Functional Assessment of Cancer Therapy – General (FACT-G) 182
Gelsinger, Jesse 9
genesis therapy 9
genetic testing 315–16, 322–3
genomics 322
GISSI 1 trial 315
Global Cooperation Group (GCG) 321
global health concerns 314–23
Good Clinical Practice (GCP) 50–71
guidelines 59–60
local laws 60–1
regulations 50–8
responsibilities 62–70
sources of information and guidance 70–1
see also International Conference on Harmonisation (ICH) E6 guidelines for Good Clinical Practice
GUSTO 1 trial 315
health information
de-identification 282, 284, 310
individually identifiable 282
privacy 9, 54–6, 282
protected see protected health information
subject identifiers 284
see also confidentiality; data
Health Insurance Portability and Accountability Act 1996 (HIPAA) 9, 54–6, 378
clinical trial data 282–4
consent requirements 90–2, 97
IRB responsibilities and 109
see also Privacy Rule
Helsinki declaration see Declaration of Helsinki
HIPAA see Health Insurance Portability and Accountability Act 1996
horse, Jim 2
Humanitarian Device Exemption (HDE) 36
humanitarian use devices 36
human subject protection regulations
assurance of compliance 53–4
Title 21 51, 370
Title 21 and Title 45 compared 52–3
Title 45 51–2, 374–5
ICH see International Conference on Harmonisation
IDE see Investigational Device Exemption
identifiers, subject 284
incentives
Clinical Research Coordinators 171
research subjects 113
inclusion criteria 191
IND see Investigational New Drug independent ethics committees (IEC) 67, 102
see also Institutional Review Board
information, health see health information
Information Sheets, FDA 71
informed consent 73–99
components 75–6
continuing 97–9, 233
defined 74–5
documentation 82–5, 96–7
emergency research exceptions 79–80, 111–12
ethical codes 75–7, 329–30, 336–8, 341
forms see consent forms
HIPAA/Privacy Rule
requirements 90–2
historic studies without 74
illiterate subjects 96
individual exceptions 79
IRB review 108, 250
obtaining 95–6, 225–6
process 92–7, 98
regulatory requirements 60, 77–92, 360–1
required elements 80–2
staff responsible for obtaining 96
voluntariness 76, 96, 337–8
vulnerable subjects 81, 85–90
waiver of requirement 80, 82, 111–12
in-house monitoring 152–4
initiation visits 143–4, 146–7
inspections 142, 154, 157–62
common findings 161
findings and reports 159–62
investigator-directed 159
regulations and guidelines 155
study-directed 159
institutional charges 208
Institutional Review Board (IRB) 101–20
accreditation 119–20
activities 107–10
adverse event reporting to 110, 116
awareness of community attitudes 105
Central (CIRB) 176
communication with investigators 116–17, 258
communication with sponsors 117–18
conflicts of interest 68, 105–6, 168–9
defined 102
external 175
final reports to 117, 241, 264, 265
independent 104, 175
information provision by 70
local 104, 175
membership 104–7

- membership documentation/assurance 251
- non-scientific members 105
- outside experts 106–7
- progress reports to 258
- records and reports 118–19
- registration 120
- regulations 371
- responsibilities 67–8, 117
- safety reports to 109–10, 116, 137, 258
- types 103–4
- unanticipated problem reporting to 109–10, 116, 128
- written procedures 110, 118–19

Institutional Review Board (IRB) review/approval 107–9, 111–15
adverse events/unanticipated problems 115, 135–6
annual renewals 258
approval letter 250–1, 252
assent by children 90
consent form revisions 99, 257
continuing review, after study approval 114–15
correspondence 258
documentation 250–3
emergency research 80, 111–12
exempt studies 113–14
expedited review 112–13, 256
full committee review 111–12
informed consent procedures 108, 250, 251, 252–3
medical device studies 32, 34, 117–18
protocol amendments 115, 256
protocols 68, 113, 115, 179–80
studies involving prisoners 88
subject payments and incentives 113
subject recruitment
- advertisements and educational materials 258
submission requirements 113, 215–16, 250
treatment use of investigational drugs 25
vulnerable subject protection 106
waiver of informed consent 80, 111–12

- integrity of investigators 167
- intention-to-treat (ITT) principle 194–5
- interactive voice response system (IVRS) 187, 230, 297
- interim analysis 195–6
- international clinical trials 314–23
- concerns about 321–2
- ethical/cultural issues 316–17
- ethnic/racial differences 315–16
- future efforts 322–3
- importance 317–19
- regulations 320–1

International Committee of Medical Journal Editors (ICMJE) 10
International Conference on Harmonisation (ICH) 8, 320–1, 377
International Conference on Harmonisation (ICH) E6
guidelines for Good Clinical Practice 8, 59–60, 320–1, 376
adverse event reporting 124
audits and inspections 155
CFR regulations compared 60
data handling 284–5, 294, 302
essential documents 246
informed consent 78, 81–2, 83, 97, 361
investigator responsibilities 67
IRBs 67–8, 102, 103
monitoring 142
record retention 308
vulnerable subjects 87
Investigational Device Exemption (IDE) application 34
regulations 30, 34–5, 373–4
treatment application 37
Investigational Device Exemption (IDE) studies
- audits and inspections 155, 157
- exempt 34–5
- financial disclosure 57
- investigator agreement 65, 70, 249–50
- investigator responsibilities 65
- protocols 178
- record retention 266, 267
- sponsor responsibilities 70, 138–9
- transfer of record retention responsibility 267
- see also device trials
- investigational devices see devices, study
- investigational drugs see drugs and biologics, study
- Investigational New Drug(s) (IND) compassionat(e) (non-research) use 25
- emergency use 25
- safety reports 137, 138
- treatment use 24–5
- see also drugs and biologics, study
- Investigational New Drug (IND) applications 16–17, 21, 372–3
- studies not requiring 178–9
- study protocols 178
- Investigational New Drug (IND) studies
- audits and inspections 156, 157
- clinical holds 17
- exploratory 17–18
- financial disclosure regulations 57

- 401
Investigational New Drug (IND) studies (continued)

- investigator responsibilities 62–5
- record retention 266, 267
- sponsor responsibilities 69–70, 137

See also drug trials

- investigational products/articles see test products/articles
- investigative site see site, study investigator(s)
  - adverse event/unanticipated problem reporting 124, 129–35
  - communication with IRB 116–17
  - definitions 62, 164
  - directed inspections 159
  - discontinuing participation 70
  - evaluating time requirements 202
- FDA inspections 159–62
- financial disclosure regulations 57, 58
- Form FDA 1572 commitments 248
  - new, during study 257
  - recordkeeping and record retention 197
  - responsibilities 62–7, 164
  - Statement of see Form FDA 1572
  - statement of qualification 249–50
- investigator agreement 65, 70, 249–50
  - change of PI 267
  - see also Principal Investigators; subinvestigators
  - investigator agreement 65, 70, 249–50
  - change of PI 267
  - see also Principal Investigators; subinvestigators
  - investigator agreement 65, 70, 249–50
  - change of PI 267
  - see also Principal Investigators; subinvestigators

Jim (the horse) 2

Justice 7, 190–1, 335–6

Kefauver–Harris Amendment 5, 14
Kelsey, Frances Oldham 4–5, 320

Language
- plain 92, 93, 94
- translation requirements 61, 94
- understandability requirements 78, 89
- legal rights 94
- legislation
  - historical timeline 2–10
  - local 60–1

Letters
- of agreement 247
- to health care provider 228
to the file 294
follow-up, on-site monitors 151, 152
IRB approval 250–1, 252
safety/investigator alert 137
warning 162
life-saving/extending treatment 195
life-threatening situations, informed consent 79–80, 111–12
local factors, sensitivity to 175
local laws 60–1
longitudinal studies 190
lost to follow-up 193, 237–8

Maintenance phase, study 230–40
market exclusivity, pediatric drug studies 8–9, 10
marketing
- biologics license application 21
- medical device regulations 33–5
- new drug application 20–1
- masking (blinding) 187–8
materials, study destruction or return 241

IRB review 108, 113, 216
management 239
see also subject materials; supplies, study
MedDRA 294, 295
Medical Device Amendments, Food, Drug and Cosmetic Act 7, 27
medical devices see devices
Medical Device User Fee and Modernization Act 2002 (MDUFMA) 28
medical licensure form 248, 249
medical records
- data recorded in 290
documentation of consent 97
screening for potential subjects 221–3
staffing requirements 204
MedWatch 41–2, 43, 378
- forms 42–3, 44–5
meetings
- study team 219, 239–40
- see also Investigator Meetings
Mesmer, Franz 188
minimal risk 107–8, 114
minimization algorithm 186
minority groups, inclusion in clinical research 53
minor
- consent/assent by 89–90
- emancipated 89
- see also children
minutes, study team meetings 263
misconduct, research 159
monitoring 142–54, 197
- in-house 152–4
- on-site 142, 144–51
- plan 143–4
- regulatory requirements 142
- monitors 142, 143
- communication with 240
- on-site visits 144–51
- responsibilities 144
- space requirements 175
multi-center trials
- international 314–23
- reporting unanticipated problems 133–5
MURDOCK longitudinal study 190
NAI (No Action Indicated) 161
National Cancer Institute (NCI) 176, 295
National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research 6, 7, 332–40 see also Belmont Report (1979)

National Health and Nutrition Examination Survey 190

National Heart, Lung, and Blood Institute (NHLBI) 189

National Institutes of Health (NIH) funding of clinical research 52 protocol templates 180 Public Access Policy 10

National Research Act 1974 6

Nazis, medical experiments 3–4

NDA see New Drug Applications

neonates consent for research on 87–8 regulations protecting 53, 375

New Drug Applications (NDA) 20–1 approvals in 2008 24 fast-track/priority review 23–4, 25, 26 FDA review procedures 21–4 new drugs application to market 20–1 development process 14–26 NIH see National Institutes of Health NIH Revitalization Act 1993 53 No Action Indicated (NAI) 161 nonconcurrent studies see retrospective studies note to the file 294

Notice of Claimed Investigational Exemption for a New Drug 16–17

Nuremberg Code 4, 77, 341

Nuremberg trials 4, 77

OAI (Official Action Indicated) 161–2 objectives, study 181–3 see also endpoints observational studies 183, 188–90

Office for Human Research Protection (OHCHR) 9 assurance of compliance 53–4 IRB registration and oversight 119, 120 reporting unanticipated problems to 110, 128, 136

Secretary's Advisory Committee on Human Research Protections (SACHRP) 108 office space 173–4, 175

Official Action Indicated (OAI) 161–2 online resources 71 on-site monitoring 142, 144–51, 197 close-out/study completion visits 149–51 documentation 151, 263 evaluating time requirements 204 follow-up letters 151, 152 initiation visits 146–7 periodic visits 147–9, 150 pre-study visits 145–6 types of visits 145–51 open-label studies 186 organizational skills 172 organizational structure, study 180–1, 214 sample chart 214

Orphan Drug Act 1983 7, 26 orphan drugs (orphan products) 25–6 approvals in 2008 24 defined 25–6 fast-track review 26

overhead costs 208 package inserts, adverse event information 125 packaging, study drug 273 packing invoice, study drug 274, 275 parents, permission from 89–90 patient-reported outcomes (PRO) 144, 302 payments budget considerations 206–7 Clinical Research Coordinators 171 trial subjects 113 Pediatric Research Equity Act 2003 10

Pediatric Rule 8, 10 periodic monitoring visits 147–9, 150, 344 permission, from parents 89–90 personnel, study see staff, study pharmacists 204, 210, 217, 277 pharmacodynamics (PD) testing 17, 18 pharmacogenetics 315–16 pharmacokinetics (PK) testing 17, 18, 19 pharmacy charges 208 phase 0 studies 17–18 phase 1 studies 18–19 phase 2 studies 19 phase 2a studies 20 phase 2b studies 20 phase 3 studies 19–20 phase 3b studies 20 phase 4 postmarketing studies 40–1 phocomelia 5, 320 PI see Principal Investigators pilot studies 20 pivotal trials 20 placebo effect 187 placebos 184, 331 plagiarism 159 pocket reference cards 224, 225 population, study 190–1 evaluating 201 see also subject(s) postmarketing surveillance 39–43 see also adverse event reporting power, study 193 pre-clinical studies 15 pregnant women informed consent 87–8 regulations protecting 53, 375 Premarket Approval (PMA), medical devices 29, 30, 34, 35 Premarket Notification (PMN), medical devices 29, 33–4 pre-study monitoring visits 143–4, 145–6 Principal Investigators (PIs) 164–9 activities 213–42 agreement with sponsor see investigator agreement characteristics of effective 165–7 conflicts of interest 167–9 data handling 287, 295, 309 delegation to CRCs 169, 171 ensuring subject retention 237 estimating costs 210 FDA inspections 157 Form FDA 1572 completion 248–50

403
Secretary’s Advisory Committee on Human Research Protections (SACHRP) 108
selection of subjects 108, 190–1, 339–40
serious adverse event(s) (SAE) 126–7, 131
IRB responsibilities 135–6
source document verification 153
serious adverse event (SAE) report forms 133, 134, 259–61, 302
submissions 307
serious adverse event (SAE) reporting 231
CRC responsibilities 204
electronic (eSAE) 297
expedited 131–3
investigator responsibilities 130, 131–3
IRB responsibilities 136
SF-36 182
sham procedures 184–5
Signature and Delegation Log 262, 263, 354
signatures, electronic 286, 298, 370
Singapore, clinical trial process 368–9
single-blind study 187
site, study 173–5
additional space 175, 205–6
competing trials 224–5
data handling 287–308
equipment 174, 205–6
estimating costs/charges 208
feasibility assessment 211–12
implementing protocol-required procedures 179
monitoring see on-site monitoring
storage space 174
workspace for CRC 173–4
Site Demographics Form 255
Site Information Sheet 255
site study file 246, 266–9
maintenance 240
review at close-out 241
sample organization 267–9
see also documents, study
Site Visit Logs 151, 262, 263, 354
site visit reports 151
Society of Clinical Research Associates (SoCRA) 170
source data 144, 288
forms 229, 231, 290, 291, 348
source documents 144, 261–3
defined 263
monitoring strategies 143
recording data in 287–90
removal of identifiers 154
verification 144, 153–4, 308–9
space requirements 174–5, 205–6
specimens
budget considerations 210
management 239
storage 174, 205
tests and procedures 204–5
sponsor-investigators 70
sponsors
adverse event reporting 136–9
budget considerations 206–7, 211
communication with 240
communication with IRBs 117–18
defined 67–8
documents for submission to 215
final reports to 264
financial disclosure reporting 57–8
Investigator Meetings 219
monitoring plans 143–4
quality assurance audits 142, 154, 155, 156
record retention requirements 266–7
reporting unanticipated problems 133–5
responsibilities 67–70
routine reporting 139
staff, study 169–73
appreciation by PI 167
communication methods 217–19
curriculum vitae/résumés 255
education and training 228–30
estimating costs 208, 209, 270, 345
evaluating requirements 202–4, 216–17
responsible for obtaining consent 96
start-up phase 216–19
support 173, 204, 210
see also team, study
standard operating procedures (SOPs) 142
Standards for Privacy of Individually Identifiable Health Information see Privacy Rule
start-up phase, study 215–30
state laws 60–1
Statement of Investigator see Form FDA 1572
statistics 193–7
Steering Committees, trial 178
stem cells 10, 23
storage
laboratory samples and specimens 174, 205
space, requirements 174
study devices 217
study documents 174, 206, 242
study drugs and biologics 206, 274
subinvestigators 172–3
financial disclosure regulations 57
new, during study 257
training 202
subject(s)
benefits of participation 165
budget preparation 208, 209
case histories 197, 264
compliance 233–8
Confidential Master Log 259, 260, 353
consent by see informed consent
contact information 230, 237–8, 351
data forms see data forms
discussions with potential 95, 226
drop outs 193
follow-up visits 231–3, 235
identifying potential 216, 220
illiterate 96
legal rights 94
lost to follow-up 193, 237–8
managing urgent clinical problems 239
non-English-speaking 94
numbers of 193–4
payment and incentives 113
recruitment and enrollment 219–28
subject(s) (continued)
retention 233–8
screening potential 201, 221–3
selection 108, 190–1, 339–40
unanticipated problems
involving risks to see
unanticipated problems
withdrawal 193, 235–7
see also vulnerable subjects
Subject Brochure 227, 228
subject-completed forms 302, 303
Subject Contact Information Form 236
subject identifiers 284
subject materials 226–8
additional 228
developing educational 226–7
IRB approval 253, 258
Subject Visit Calculator 231–3, 234, 350
Subject Visit Tracking Log 232, 233, 349
substantial equivalence, medical devices 33
supplies, study
estimating costs 210
storage 206
see also materials, study
support personnel 173, 204, 210
surrogate endpoints 182–3
surveys, exempt from IRB approval 114
syphilis, Tuskegee Study 3, 6, 77
team, study 216–19
appreciation by PI 167
communication methods 217–19, 239–40
evaluating requirements 202–4, 216–17
see also staff, study
telephones
documenting conversations 263
helplines 239
randomization systems 187, 230
study requirements 173
test products/articles 271–9
accountability records/forms 239, 259, 264–6
advertising claims 221
disposition 241, 266
management plan 272
storage space 174
see also devices, study; drugs and biologics, study
thalidomide 4–5, 320
therapeutic hope 95
therapeutic misconception 95
toxicity, evaluation 18–19
tracking, study devices 279
training
Clinical Research Coordinators 170
evaluating requirements 203–4
records, study site personnel 255
study site personnel 228–30
subinvestigators 202
treatment effect, clinical trials 19–20
treatment/intervention studies 183
treatment plan, study 191–2
treatment use
investigational drugs 24–5
unapproved medical devices 37
trip reports 151
Tuskegee Study of Untreated Syphilis in the Negro Male 3, 6, 77
unanticipated adverse device effects 124
expedited reporting 138–9
reporting 130, 135
unanticipated problems (involving risks to subjects or others) 127–9
defined 127
IRB responsibilities 136
reporting 109–10, 116, 127–9, 133–5, 231
review by IRBs 115
unblinding 188, 238, 277–8
undue influence 78, 96
Vaccine Adverse Event Reporting System (VAERS) 42
VAI (Voluntary Action Indicated) 161
Visit Tracking Log, subject 232, 233, 349
voluntariness of consent 76, 96, 337–8
Voluntary Action Indicated (VAI) 161
vulnerable subjects
consent 81, 85–90
defined 87, 106
federally funded research 53
Helsinki declaration 329
IRB membership and 106
regulatory protection 53, 87–90, 106, 375
wallet card 227
Warning Letters 162
Web sites, useful 71, 377–8
Western Ontario and McMaster University Osteoarthritis Index (WOMAC) 182
WHOART 294
withdrawals, study 193, 235–7
minimizing 233–5
witnesses, informed consent 83, 84, 85
WOMAC 182
women, inclusion in clinical research 53
World Health Organization (WHO) 317–18, 319
World Medical Association (WMA) 5–6
see also Declaration of Helsinki
www.ClinicalTrials.gov 10, 58